<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.911191</article-id><article-id pub-id-type="publisher-id">ACM-32780</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20191100000_65421341.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  55例多原发恶性肿瘤回顾性临床分析
  Retrospective Clinical Analysis of 55 Cases of Multiple Primary Malignant Tumors
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>云波</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>建光</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>俊启</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郑</surname><given-names>丽萍</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>淄博万杰肿瘤医院肿瘤科，山东 淄博</addr-line></aff><aff id="aff3"><addr-line>郑州大学第一附属医院放疗科，河南 郑州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>31</day><month>10</month><year>2019</year></pub-date><volume>09</volume><issue>11</issue><fpage>1238</fpage><lpage>1242</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：探讨多原发恶性肿瘤的发病情况、临床特点及与生存率之间的相关性。方法：收集我院2014年7月~2019年5月收治865例患者，其中55例为双原发或三原发恶性肿瘤，分析其病历资料。结果：多原发恶性肿瘤患者发病率为6.36%，其中双原发恶性肿瘤为49例，三原发恶性肿瘤为6例，发病率为0.69%。男性27例，女性28例，第一原发恶性肿瘤平均年龄54.84岁，第二原发恶性肿瘤平均年龄为62.7岁，第三原发恶性肿瘤平均年龄为64.33岁。结论：多原发恶性肿瘤以消化道多见，其次为肺癌。高发年龄为40~69岁之间。第一原发恶性肿瘤发病年龄与生存率成正相关，相关系数为0.51。而第二原发恶性肿瘤发病年龄与生存率成明显负相关，相关系数为−0.93。 Objective: To investigate correlation of the incidence, clinical characteristics and survival rate of multiple primary malignant tumors. Methods: 865 cases of malignant tumors were treated in our hospital from July 2014 to May 2019, 55 of them were double or triple primary malignant tumors, and their medical records were analyzed. Results: The incidence of multiple primary malignant tumors was 6.36%, including 49 cases of double primary malignant tumors and 6 cases of three primary malignant tumors. The incidence was 0.69%. There were 27 males and 28 females. The average age of the first primary malignant tumor was 54.84 years; the average age of the second primary malignant tumor was 62.7 years; and the average age of the third primary malignant tumor was 64.33 years. Conclusion: Digestive tract is the most common primary malignant tumor, followed by lung cancer. The high incidence age is between 40 and 69 years old. The age at onset of the first primary malignant tumor was positively correlated with survival rate. The correlation coefficient is 0.51. The age at onset of the second primary malignant tumor was negatively correlated with survival rate. The correlation coefficient is −0.93. 
  
 
</p></abstract><kwd-group><kwd>多原发恶性肿瘤，发病年龄，生存率, Multiple Primary Malignant Tumors</kwd><kwd> Age of Onset</kwd><kwd> Survival Rate</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>55例多原发恶性肿瘤回顾性临床分析<sup> </sup></title><p>张云波<sup>1</sup>，张建光<sup>1</sup>，刘俊启<sup>2</sup>，郑丽萍<sup>1</sup></p><p><sup>1</sup>淄博万杰肿瘤医院肿瘤科，山东 淄博</p><p><sup>2</sup>郑州大学第一附属医院放疗科，河南 郑州</p><p><img src="//html.hanspub.org/file/2-1571068x1_hanspub.png" /></p><p>收稿日期：2019年9月27日；录用日期：2019年10月24日；发布日期：2019年10月31日</p><disp-formula id="hanspub.32780-formula28"><graphic xlink:href="//html.hanspub.org/file/2-1571068x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨多原发恶性肿瘤的发病情况、临床特点及与生存率之间的相关性。方法：收集我院2014年7月~2019年5月收治865例患者，其中55例为双原发或三原发恶性肿瘤，分析其病历资料。结果：多原发恶性肿瘤患者发病率为6.36%，其中双原发恶性肿瘤为49例，三原发恶性肿瘤为6例，发病率为0.69%。男性27例，女性28例，第一原发恶性肿瘤平均年龄54.84岁，第二原发恶性肿瘤平均年龄为62.7岁，第三原发恶性肿瘤平均年龄为64.33岁。结论：多原发恶性肿瘤以消化道多见，其次为肺癌。高发年龄为40~69岁之间。第一原发恶性肿瘤发病年龄与生存率成正相关，相关系数为0.51。而第二原发恶性肿瘤发病年龄与生存率成明显负相关，相关系数为−0.93。</p><p>关键词 :多原发恶性肿瘤，发病年龄，生存率</p><disp-formula id="hanspub.32780-formula29"><graphic xlink:href="//html.hanspub.org/file/2-1571068x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-1571068x7_hanspub.png" /> <img src="//html.hanspub.org/file/2-1571068x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>多原发恶性肿瘤(multiple primary malignant tumors, MPMT)越来越受到重视。近来由于肿瘤研究和治疗技术的提高，在初次确诊肿瘤后，随着肿瘤患者存活时间延长，出现第二原发恶性肿瘤可能性增大。尽管对多原发恶性肿瘤存在不同的定义。主要依据SEER (Surveillance, Epidemiology, and End Results)和IACR/IARC (International Association of Cancer Registries and International Agency for Research on Cancer)的定义。多原发恶性肿瘤发病率在2%~17%之间。潜在的因素包括区域、生活相关、环境、遗传因素和治疗相关因素 [<xref ref-type="bibr" rid="hanspub.32780-ref1">1</xref>] 。本文对我院2014年7月~2019年5月入住恶性肿瘤患者进行统计分析。探讨发病年龄、性别、间隔时间及发病特征。以提高对多原发恶性肿瘤的认识。</p></sec><sec id="s4"><title>2. 资料和方法</title><sec id="s4_1"><title>2.1. 临床资料</title><p>选取2014年7月~2019年5月收治55例经病理证实的双原发或三原发恶性肿瘤患者。对其年龄、性别、病理分型、治疗进行回顾性分析。其中双原发恶性肿瘤为49例，三原发恶性肿瘤为7例。男性27例，女性28例，男女之比为0.96。第一原发恶性肿瘤平均年龄54.84 &#177; 12.29岁，第二原发恶性肿瘤平均年龄为62.7 &#177; 10.5岁，第三原发恶性肿瘤平均年龄为64.33岁。</p></sec><sec id="s4_2"><title>2.2. 分布情况</title><p>从肿瘤发病部位来观察，肺癌19例，乳腺癌11例，头颈部肿瘤13例，结直肠癌12例，胃癌8例，食管癌7例，卵巢癌3例，淋巴瘤2例，前列腺癌3例。子宫内膜癌4例，胆囊癌2例，肾癌1例，肾盂癌1例，胰腺癌2例，宫颈癌3例，膀胱癌3例，十二指肠癌2例，胃间质瘤2例，肝癌2例，畸胎瘤2例，腹腔类癌1例。</p></sec><sec id="s4_3"><title>2.3. 病理类型</title><p>从病理类型来观察，共117个原发病灶，67个病灶为腺癌，35个病灶为鳞癌，类癌4个，尿路上皮癌4个，小细胞癌2个，畸胎瘤2个，弥漫大B细胞淋巴瘤2个，肉瘤样癌1个。总体来看，腺癌较多。</p></sec><sec id="s4_4"><title>2.4. 治疗方法</title><p>各种治疗方法在病灶中应用，手术为70次，化疗为57次，放疗治疗在37次，内分泌治疗11次，靶向治疗5次，射频治疗2次，介入治疗1次。手术、放疗、化疗为主要治疗手段，内分泌治疗主要应用在乳腺肿瘤方面。</p></sec></sec><sec id="s5"><title>3. 临床表现</title><sec id="s5_1"><title>3.1. 发病与年龄之间关系(表1)</title><p>从表1中可以看出，主要发病年龄位于40~69岁之间，本组研究中无小于20岁患者。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Relationship between morbidity and ag</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >年龄(岁)</th><th align="center" valign="middle" >第一原发肿瘤</th><th align="center" valign="middle" >第二原发肿瘤</th><th align="center" valign="middle" >第三原发肿瘤</th></tr></thead><tr><td align="center" valign="middle" >20~29</td><td align="center" valign="middle" >1 (1.82%)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >30~39</td><td align="center" valign="middle" >3 (5.45%)</td><td align="center" valign="middle" >1 (1.82%)</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >40~49</td><td align="center" valign="middle" >15 (27.27%)</td><td align="center" valign="middle" >5 (9.1%)</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >50~59</td><td align="center" valign="middle" >18 (32.73%)</td><td align="center" valign="middle" >13 (23.64%)</td><td align="center" valign="middle" >1 (16.67%)</td></tr><tr><td align="center" valign="middle" >60~69</td><td align="center" valign="middle" >11 (20%)</td><td align="center" valign="middle" >24 (43.64%)</td><td align="center" valign="middle" >4 (66.67%)</td></tr><tr><td align="center" valign="middle" >70~79</td><td align="center" valign="middle" >5 (9.1%)</td><td align="center" valign="middle" >7 (12.73%)</td><td align="center" valign="middle" >1 (16.67%)</td></tr><tr><td align="center" valign="middle" >&gt;80</td><td align="center" valign="middle" >2 (3.64%)</td><td align="center" valign="middle" >5 (9.1%)</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >合计</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >6</td></tr></tbody></table></table-wrap><p>表1. 发病与年龄之间关系</p></sec><sec id="s5_2"><title>3.2. 发病间隔时间</title><p>第一原发恶性肿瘤与第二原发恶性肿瘤间隔时间为0~360个月，平均为95.07个月。间隔小于1年为7例，1~2年为4例，2~3年2例，3~4年为6例，4~5年为3例，间隔时间大于5年为34例。第二原发恶性肿瘤与第三原发恶性肿瘤的间隔时间为0~108个月，平均为59.83个月。</p></sec><sec id="s5_3"><title>3.3. 生存预后的统计及相关性统计</title><p>利用EXCEL对数据进行统计，中位生存期为54个月，平均为87.44个月。通过相关系数分析可见第一原发恶性肿瘤发病年龄与生存率成正相关，而第二原发恶性肿瘤发病年龄与生存率成明显负相关。生存曲线见图1，相关性统计见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Correlation coefficient analysi</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >生存率</th><th align="center" valign="middle" ></th><th align="center" valign="middle" >观察月数</th><th align="center" valign="middle" >第一肿瘤发病年龄</th><th align="center" valign="middle" >第二肿瘤发病年龄</th></tr></thead><tr><td align="center" valign="middle" >生存率</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >观察月数</td><td align="center" valign="middle" >0.726393</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >第一肿瘤发病年龄</td><td align="center" valign="middle" >0.511826</td><td align="center" valign="middle"  rowspan="2"  >P &lt; 0.005</td><td align="center" valign="middle" >0.914765</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >第二肿瘤发病年龄</td><td align="center" valign="middle" >−0.92726</td><td align="center" valign="middle" >−0.75815</td><td align="center" valign="middle" >−0.5412</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表2. 相关系数分析</p><p>图1. 55例患者Kaplan-Meier总生存曲线</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>关于多原发恶性肿瘤，国内外各种文献报道差别较大，但发病率大约在2%~17%范围内。朱莉菲等报道双重癌发病率为0.4%，三重癌发生率为0.1%，四重癌发生率为0.02% [<xref ref-type="bibr" rid="hanspub.32780-ref2">2</xref>] 。王乐等报道的三原发恶性肿瘤发病率为0.035% [<xref ref-type="bibr" rid="hanspub.32780-ref3">3</xref>] 。Owen LJ早在1921年对3000例恶性肿瘤患者进行分析，发现多原发恶性肿瘤的发病率为4.7% [<xref ref-type="bibr" rid="hanspub.32780-ref4">4</xref>] 。奥婷等报道了肺癌的多原发恶性肿瘤占肺癌患者的1.96% [<xref ref-type="bibr" rid="hanspub.32780-ref5">5</xref>] 。我们统计的发病率为6.36%，三原发恶性肿瘤发病率为0.69%。有文献报道多原发恶性肿瘤的发病率男女之比为0.9:1~3.5:1 [<xref ref-type="bibr" rid="hanspub.32780-ref6">6</xref>] 。也有报道男女之比无相关性 [<xref ref-type="bibr" rid="hanspub.32780-ref7">7</xref>] 。本研究中男女之比为0.96。Nicholas Donin等统计21,161,163例确诊患者，发现有170,865例发展为第二原发恶性肿瘤，占比为8.1%。发现膀胱癌存活的患者具有高风险，10年和20年第二原发恶性肿瘤风险率分别为19%和34% [<xref ref-type="bibr" rid="hanspub.32780-ref8">8</xref>] 。值得注意是第二原发恶性肿瘤相关死亡率非常高，甚至超过了确诊的单一癌症患者。从本研究中可见生存率与第一原发恶性肿瘤发病年龄成正相关，而第二原发恶性肿瘤发病年龄与生存率成明显负相关。</p><p>基于包括诊断、治疗和人口统计等各种综合因素分析，在未来几年，多原发性肿瘤初诊时患病率会增加。随着随访时间的延长，多原发肿瘤的发病报道也会增加。由于多种独特的因素，包括遗传因素、病因暴露以及化疗和放疗后期效应，癌症幸存者可能特别容易发展为第二原发恶性肿瘤 [<xref ref-type="bibr" rid="hanspub.32780-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.32780-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.32780-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.32780-ref12">12</xref>] 。同样需要重点关注一些具有多原发肿瘤高发风险因素的特殊人群。例如有吸烟或酗酒史的男性患者、一些具有家族肿瘤史患者和早期肿瘤。在生殖细胞肿瘤和霍奇金淋巴瘤患者中观察到与治疗相关的第二原发恶性肿瘤，对于靶向药物是否会导致第二肿瘤目前尚不清楚。对一些高危患者应当进行筛查，BRCA1和BRCA2突变有发展为多原发性肿瘤的风险，可每年通过乳腺核磁检查进行筛查和进行卵巢癌的筛查，Lynch综合征应当尽早和多次进行肠镜检查 [<xref ref-type="bibr" rid="hanspub.32780-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.32780-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.32780-ref15">15</xref>] 。</p><p>综上所述，多原发恶性肿瘤有独特的流行病学和发病特点，预后较单一肿瘤差。对一些特殊人群需要进行严密监测，及时检查。对一些有基因突变的患者应早期筛查，增加检查频次。以便早期发现肿瘤，提高治疗生存率。</p></sec><sec id="s7"><title>基金项目</title><p>国家自然科学基金资助项目(81703158)。</p></sec><sec id="s8"><title>文章引用</title><p>张云波,张建光,刘俊启,郑丽萍. 55例多原发恶性肿瘤回顾性临床分析Retrospective Clinical Analysis of 55 Cases of Multiple Primary Malignant Tumors[J]. 临床医学进展, 2019, 09(11): 1238-1242. https://doi.org/10.12677/ACM.2019.911191</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.32780-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Vogt, A., Schmid, S., Heinimann, K., et al. (2017) Multiple Primary Tumours: Challenges and Approaches, a Review. ESMO Open, 2, e000172. &lt;br&gt;https://doi.org/10.1136/esmoopen-2017-000172</mixed-citation></ref><ref id="hanspub.32780-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">朱莉菲, 薛鹏, 王理伟, 等. 65例多原发癌的临床回顾性研究[J]. 复旦学报(医学版), 2010, 37(5): 592-593.</mixed-citation></ref><ref id="hanspub.32780-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">王乐, 王婷, 孟磊, 等. 三原发恶性肿瘤14例临床分析[J]. 现代肿瘤医学, 2017, 25(14): 2305-2308.</mixed-citation></ref><ref id="hanspub.32780-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Owen, L.J. (1921) Multiple Malignant Ne-oplasms. The Journal of American Medical Association, 76, 1329-1333.  
&lt;br&gt;https://doi.org/10.1001/jama.1921.02630200001001</mixed-citation></ref><ref id="hanspub.32780-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">奥婷, 孙军平, 张明月, 等. 肺癌合并其他原发恶性肿瘤55例发病特点分析[J]. 解放军医学院学报, 2016, 37(3): 226-241.</mixed-citation></ref><ref id="hanspub.32780-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Zakai, N.A., Katz, R., Hirsch, C., et al. (2005) A Prospective Study of Anemia Status, Hemoglobin Concentration, and Mortality in an Elderly Cohort: The Car-diovascular Health Study. Archives of Internal Medicine, 165, 2214-2220.  
&lt;br&gt;https://doi.org/10.1001/archinte.165.19.2214</mixed-citation></ref><ref id="hanspub.32780-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Wechsler, L.R. (2011) Imaging Evaluation of Acute Ischemic Stroke. Stroke, 42, S12-S15.  
&lt;br&gt;https://doi.org/10.1161/STROKEAHA.110.599555</mixed-citation></ref><ref id="hanspub.32780-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Donin, N., Filson, C., Drakaki, A., et al. (2016) Risk of Second Primary Malignancies among Cancer Survivors in the United States, 1992 through 2008. Cancer, 122, 3075-3086. &lt;br&gt;https://doi.org/10.1002/cncr.30164</mixed-citation></ref><ref id="hanspub.32780-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Tiwari, A.K., Roy, H.K. and Lynch, H.T. (2016) Lynch Syn-drome in the 21st Century: Clinical Perspectives. QJM, 109, 151-158. &lt;br&gt;https://doi.org/10.1093/qjmed/hcv137</mixed-citation></ref><ref id="hanspub.32780-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Lu, C.H., Lee, K.D., Chen, P.T., et al. (2013) Second Primary Malig-nancies Following Thyroid Cancer: A Population-Based Study in Taiwan. European Journal of Endocrinology, 169, 577-585. &lt;br&gt;https://doi.org/10.1530/EJE-13-0309</mixed-citation></ref><ref id="hanspub.32780-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Berrington de Gonzalez, A., Curtis, R.E., Kry, S.F., et al. (2011) Proportion of Second Cancers Attributable to Radiotherapy Treatment in Adults: A Cohort Study in the US SEER Cancer Registries. The Lancet Oncology, 12, 353-360.  
&lt;br&gt;https://doi.org/10.1016/S1470-2045(11)70061-4</mixed-citation></ref><ref id="hanspub.32780-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Schairer, C., Hisada, M., Chen, B.E., et al. (2007) Compara-tive Mortality for 621 Second Cancers in 29356 Testicular Cancer Survivors and 12420 Matched First Cancers. National Cancer Institute, 99, 1248-1256.  
&lt;br&gt;https://doi.org/10.1093/jnci/djm081</mixed-citation></ref><ref id="hanspub.32780-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Burke, W., Daly, M., Garber, J., et al. (1997) Recommendations for Fol-low-Up Care of Individuals with an Inherited Predisposition to Cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. The Journal of American Medical Association, 277, 997-1003. &lt;br&gt;https://doi.org/10.1001/jama.1997.03540360065034</mixed-citation></ref><ref id="hanspub.32780-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Saslow, D., Boetes, C., Burke, W., et al. (2007) Ameri-can Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography. CA: A Cancer Journal for Clinicians, 57, 75-89. &lt;br&gt;https://doi.org/10.3322/canjclin.57.2.75</mixed-citation></ref><ref id="hanspub.32780-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Giardiello, F.M., Allen, J.I., Axilbund, J.E., et al. (2014) Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Diseases of the Colon &amp; Rectum, 57, 1025-1048. &lt;br&gt;https://doi.org/10.1097/DCR.000000000000000</mixed-citation></ref></ref-list></back></article>